Affiner les résultats

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings

Palmer, Andrew J. ; Annemans, Lieven ; Roze, Stéphane ; Lamotte, Mark ; Rodby, Roger A. ; Cordonnier, Daniel J.

In: Nephrology Dialysis Transplantation, 2003, vol. 18, no. 10, p. 2059-2066

Direct medical costs of type 2 diabetes and its complications in Switzerland

Schmitt-Koopmann, Irmgard ; Schwenkglenks, Matthias ; Spinas, Giatgen A. ; Szucs, Thomas D.

In: The European Journal of Public Health, 2004, vol. 14, no. 1, p. 3-9

The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses

Anz, David ; Kruger, S. ; Haubner, S. ; Rapp, Moritz ; Bourquin, Carole ; Endres, Stefan

In: Diabetes, Obesity and Metabolism, 2014, vol. 16, no. 6, p. 569–572

Inhibitors of dipeptidylpeptidase IV (DPP-IV) represent a novel class of frequently used anti-diabetic drugs. In addition to its function in metabolic regulation, DPP-IV also plays a role in the immune system. Whether the DPP-IV inhibitors sitagliptin, vildagliptin or saxagliptin impair immune responses is, however, currently unknown. Here, we investigated the effect of these agents on both...

Regulation of fat storage via suppressed thermogenesis: a thrifty phenotype that predisposes individuals with catch-up growth to insulin resistance and obesity

Dulloo, Abdul G.

In: Hormone Research, 2006, vol. 65, no. 3, p. 90-97

Catch-up growth during infancy and childhood is increasingly recognized as a major risk factor for later development of insulin-related complications and chronic diseases, namely abdominal obesity, type 2 diabetes and cardiovascular disease. As catch-up growth per se is characterized by insulin resistance, hyperinsulinaemia and an accelerated rate of fat storage (i.e., catch-up fat) even in...